在CRS+HIPEC患者的术后免疫疗法的有效性:基于倾向性得分匹配的单中心回顾性研究

Xin-Li Liang1,2, Yan-Dong Su2, Yu-Bin Fu2

  • 1Department of Peritoneal Oncology, Cancer Center of Beijing Tsinghua Changgung Hospital & School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, Beijing, China.

PubMed
概括

术后免疫疗法显著改善了恶性腹膜间皮瘤患者在细胞减小手术和高热腹膜内化疗后的生存率. 对于这些罕见的癌症,这种方法比单独的化疗更有利于存活.